We are live on ! Find out more
KAM

Kazazian Asset Management Portfolio holdings

AUM $91.5M
1-Year Est. Return 35.36%
This Fund
S&P 500
This Quarter Est. Return
-3.92%
1 Year Est. Return
+35.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.4M
AUM Growth
-$2.44M
Cap. Flow
+$4.55M
Cap. Flow %
4.76%
Top 10 Hldgs %
49.5%
Holding
93
New
11
Increased
17
Reduced
38
Closed
8

Top Buys

Rank Stock Value
1
XOP icon
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
+$2.15M
2
BIIB icon
Biogen
BIIB
+$1.77M
3
INTC icon
Intel
INTC
+$1.21M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$993K
5
ORCL icon
Oracle
ORCL
+$903K

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$976K
2
PPLI
People Inc
PPLI
+$900K
3
MU icon
Micron Technology
MU
+$884K
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$836K
5
GM icon
General Motors
GM
+$688K

Sector Composition

Rank Sector Weight
1 Healthcare 28.25%
2 Consumer Discretionary 9.29%
3 Financials 8.39%
4 Technology 6.79%
5 Communication Services 5.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PDCO
76
DELISTED
Patterson Companies, Inc.
PDCO
$145K 0.15%
+6,506
New +$202K
ESI icon
77
Element Solutions
ESI
$9.23B
$121K 0.13%
12,597
-519
-4% -$5.54K
GTE icon
78
Gran Tierra Energy
GTE
$317M
$121K 0.13%
4,345
-444
-9% -$12K
SAN icon
79
Banco Santander
SAN
$210B
$94K 0.1%
14,904
-1,554
-9% -$10.3K
CLF icon
80
Cleveland-Cliffs
CLF
$6.99B
$75K 0.08%
10,785
-2,376
-18% -$17.8K
OMED
81
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$68K 0.07%
21,289
+1,777
+9% +$4.9K
NERV icon
82
Minerva Neurosciences
NERV
$199M
$65K 0.07%
1,301
– –
MTL.PR
83
DELISTED
Mechel PAO American Depositary Shares (each representing one-half of a Preferred Share)
MTL.PR
$57K 0.06%
44,298
– –
EQS icon
84
Equus Total Return
EQS
$16.7M
$45K 0.05%
19,073
– –
GMO
85
DELISTED
General Moly, Inc.
GMO
$8K 0.01%
20,895
– –
PPLI
86
People Inc
PPLI
$3.1B
– –
-41,205
Closed -$900K
MU icon
87
Micron Technology
MU
$991B
– –
-21,498
Closed -$884K
PMT
88
PennyMac Mortgage Investment
PMT
$842M
– –
-32,417
Closed -$521K
RCKT icon
89
Rocket Pharmaceuticals
RCKT
$394M
– –
-6,504
Closed -$68K
UA icon
90
Under Armour Class C
UA
$2.53B
– –
-20,885
Closed -$278K
VRTX icon
91
Vertex Pharmaceuticals
VRTX
$126B
– –
-6,512
Closed -$976K
BIVV
92
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-5,201
Closed -$280K
JUNO
93
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-18,281
Closed -$836K
1 2 3
4

Similar funds

MRP
Measured Risk Portfolios San Diego, California $91.4M AUM 0.88% 1-Year Est. Return
ITG
Index Technologies Group New York $91.8M AUM
MA
Marquette Associates Chicago, Illinois $91.9M AUM 13.47% 1-Year Est. Return
AW
Aspirean Wealth Mill Valley, California $92.1M AUM
SPCM
Spruce Point Capital Management New York $90.9M AUM
ML
MLP3 LLC Linwood, New Jersey $90.7M AUM
ICM
Incision Capital Management San Francisco, California $90.6M AUM
ACMC
Anchor Capital Management Company Raleigh, North Carolina $92.7M AUM 19.36% 1-Year Est. Return

Kazazian Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Kazazian Asset Management held 93 positions worth $95.4M, down 2.5% from $97.9M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Kazazian Asset Management deployed $4.55M of net new capital in Q1 2018, opening 11 new positions and adding to 17 existing holdings. Its largest new stake was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 15,000 shares worth $2.11M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was General Motors, an estimated $688K trimmed.

  • Kazazian Asset Management's largest Q1 2018 buy was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 15,000 shares worth $2.11M.
  • Kazazian Asset Management added most to Biogen in Q1 2018, an estimated $1.77M increase.
  • Kazazian Asset Management's biggest Q1 2018 reduction was General Motors, cutting an estimated $688K.
  • Kazazian Asset Management fully exited Vertex Pharmaceuticals in Q1 2018, selling an estimated $976K.
  • Kazazian Asset Management's ten largest holdings make up 50% of its $95.4M portfolio in Q1 2018.
  • Kazazian Asset Management opened 11 new positions and closed 8 in Q1 2018.
  • Kazazian Asset Management's portfolio value fell 2.5% quarter-over-quarter to $95.4M.

Based on Kazazian Asset Management's 13F filing for Q1 2018, filed 15 May 2018.